Author

Malcolm Moore

Observed names: M Moore, M. Moore

Institutions: BC Cancer Agency, University Health Network, Princess Margaret Cancer Centre

Observed institutions: University of Verona, Fox Chase Cancer Center, BC Cancer Agency, DuPont (United States), University Health Network, Mayo Clinic, The University of Texas MD Anderson Cancer Center, University of Liverpool, Aix-Marseille Université, Heidelberg University, University of Michigan, Princess Margaret Cancer Centre, Prince of Wales Hospital, Royal Marsden Hospital, Institut Claudius Regaud, Institut Paoli-Calmettes, Georgia Cancer Specialists, University of Birmingham

ORCID: 0009-0009-2679-7437

Observed ORCID: 0009-0009-2679-7437

OpenAlex ID: A5111758539

Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer

2010 · Daniel J. Sargent, Silvia Marsoni, et al. · Journal of Clinical Oncology · 1,625

PDF

No Association Between Hepatitis C and B–Cell Lymphoma

1999 · Jane D. Collier, Brent Zanke, et al. · Hepatology · 112

ESPAC-3(v2): A multicenter, international, open-label, randomized controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma

2009 · J. Neoptolemos, M. Büchler, et al. · Journal of Clinical Oncology · 72

Multicenter Phase II Study of Brequinar Sodium in Patients with Advanced Breast Cancer

1993 · Robert Cody, David Stewart, et al. · American Journal of Clinical Oncology · 44

A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours

2006 · Tara Baetz, Elizabeth Eisenhauer, et al. · Investigational New Drugs · 30

Clinical experience with gemcitabine in pancreatic carcinoma.

1997 · M Michael, M Moore · PubMed · 17

Vascular Resection for Pancreas Cancer

2024 · David Henault, Holden Kunde, et al. · Annals of Surgery · 12

A phase II study to determine the efficacy and tolerability of intravenous ZD9331 in heavily pretreated patients with ovarian cancer

2003 · J.S Rader, D Clarke-Pearson, et al. · Gynecologic Oncology · 11

Phase II trial of veliparib (V) in patients (pts) with previously treated BRCA or PALB2-mutated (mut) pancreas adenocarcinoma (PC).

2015 · Maeve Aine Lowery, David Paul Kelsen, et al. · Journal of Clinical Oncology · 10

Post-chemotheraphy Retroperitoneal Lymph Node Dissection for Testicular Germ Cell Tumors: Is Surgery Indicated in All and Is Bilateral Template Necessary? Princess Margaret Hospital Experience

2009 · David Kakiashvili, Lynn Anson-Cartwright, et al. · The Journal of Urology · 9

The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative

2025 · Tess Aalto, Maria Abacan, et al. · Cancer Cell · 5

719: Outcome in Stage I Seminoma Managed by Radiation Therapy and Surveillance

2005 · Padraig Warde, Mary Gospodarowicz, et al. · The Journal of Urology · 4

PDF

Phase III Trial (MPACT) of Weekly Nab-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer: Influence of Prognostic Factors on Survival

2013 · Josep Tabernero, Daniel Von Hoff, et al. · Annals of Oncology · 2

Tu1953 Nab-Paclitaxel Plus Gemcitabine vs Gemcitabine Alone for Resected Pancreatic Cancer in a Phase III Trial (APACT)

2015 · Margaret Tempero, Dana Cardin, et al. · Gastroenterology · 1

Mp10-10 Outcomes of Progression on Surveillance for Clinical Stage I Nonseminomatous Germ Cell Tumours

2015 · Madhur Nayan, Michael A.S. Jewett, et al. · The Journal of Urology · 1

Response to letter ‘Outcome of second-line chemotherapy for biliary tract cancer’

2012 · Thomas Walter, Anne M. Horgan, et al. · European Journal of Cancer · 1

944 Post-chemotherapy Retroperitoneal Lymph Node Dissection for Testicular Germ Cell Tumours: Is Surgery Indicated in All and Is Bilateral Template Necessary?

2009 · D. Kakiashvili, L. Anson-Cartwright, et al. · European Urology Supplements · 1

Non-risk Adapted Surveillance in Stage I Nonseminomatous Germ Cell Tumours (nsgct): Improved Recent Outcomes

2008 · M. Jewett, M. Moore, et al. · European Urology Supplements · 1

NanoString profiling of DNA repair and apoptosis genes in testicular germ cell tumours with divergent chemotherapy outcomes

2026 · Nadia Hitchen, Philippe L. Bedard, et al. · Therapeutic Advances in Medical Oncology

Durvalumab and oleclumab in resectable pancreatic ductal adenocarcinoma: A window of opportunity trial (DORA).

2026 · Erica Sophia Tsang, Beatriz Anton Pascual, et al. · Journal of Clinical Oncology

1040P Outcomes of male patients with relapsed/refractory germ cell tumors treated with tandem high-dose chemotherapy and autologous stem cell transplantation: Princess Margaret Cancer Centre 16 year experience

2025 · J. Nolan, J. Kuruvilla, et al. · Annals of Oncology

A retrospective review of the University Health Network (UHN) multimodal treatment experience with extended resection of pancreatic ductal adenocarcinoma (PDAC) in patients with arterial involvement.

2015 · Amélie Tremblay St-Germain, Adrian Fox, et al. · Journal of Clinical Oncology

APACT: A Phase III Trial of Nab-Paclitaxel (nab-P) Plus Gemcitabine (Gem) Versus Gem Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (PC)

2014 · Margaret Tempero, Dana Cardin, et al. · The American Journal of Gastroenterology

Apact: a Phase III Trial of Nab-Paclitaxel (Nab-P) Plus Gemcitabine (Gem) Vs Gem Alone for Resected Pancreatic Cancer (Pc)

2014 · M.A. Tempero, D. Cardin, et al. · Annals of Oncology

The International Society of Gastrointestinal Oncology Selected Proceedings and Abstracts From the Eleventh Annual Conference.

2014 · Malcolm Moore · Europe PMC (PubMed Central)

Works count: 33

Citation count: 1,958

H-index: 9

I10-index: 9